CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30

Size: px
Start display at page:

Download "CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30"

Transcription

1 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 2 METHODOLOGY... 2 ANALYST CREDENTIALS... 2 SCOPE OF REPORT... 2 INFORMATION SOURCES... 3 RELATED BCC REPORTS... 3 BCC ONLINE SERVICES... 3 DISCLAIMER... 4 CHAPTER TWO: SUMMARY... 5 SUMMARY... 5 SUMMARY TABLE U.S. FORECAST OF SPONSORED CLINICAL TRIALS MARKET, THROUGH SUMMARY FIGURE U.S. FORECAST OF SPONSORED CLINICAL TRIALS MARKET, ($ BILLIONS)... 7 CHAPTER THREE: OVERVIEW... 8 TYPES OF CLINICAL TRIALS... 8 CLINICAL TRIAL PHASES... 8 WHO SPONSORS CLINICAL TRIALS?... 8 TABLE 1 U.S. FORECAST OF SPONSORED CLINICAL TRIALS, THROUGH FIGURE 1 U.S. SPONSORED CLINICAL TRIALS MARKET, ($ BILLIONS)... 9 FIGURE 2 DRUG DEVELOPMENT TIME LINE TABLE 2 PHASES OF THE CLINICAL TRIAL PHASE I PHASE II PHASE III PHASE IV/POST-MARKETING TRIALS FACTORS AFFECTING STUDY SIZE PHYSICIAN AND PATIENT RECRUITMENT U.S. GOVERNMENT REGULATIONS PHARMACEUTICALS AND BIOLOGICS TABLE 3 U.S. LAWS AFFECTING DRUG APPROVAL TIMES Additional U.S. Laws Affecting Clinical Trials Health Insurance Portability and Accountability Act of 1996 (HIPAA) Best Pharmaceuticals for Children Act (BPCA),

2 TABLE 4 TOTAL APPROVED ACTIVE MOIETIES WITH NO MARKETING PROTECTION FOR WHICH FDA HAS ISSUED A WRITTEN REQUEST FOOD AND DRUG ADMINISTRATION (FDA) Background Center for Biologics Evaluation and Research (CBER) CBER and Bioterrorism Center for Drug Evaluation and Research (CDER) CDER and Bioterrorism Critical Path Initiative (CPI) MEDICAL DEVICES Center for Devices and Radiologic Health (CDRH) Articles Subject to Medical Device Amendments Classification of Devices (General Section 513) Class I General Controls Class II Special Controls Class III Expedited Review FIGURE 3 NEW DRUG DEVELOPMENT TABLE 5 CDER APPROVAL TIMES FOR PRIORITY AND STANDARD NDAS AND BLAS, CALENDAR YEARS, Expedited Development and Review TABLE 6 FIRST CYCLE APPROVAL RATE FOR OVERALL STUDY COHORT BY YEAR, Subpart E Accelerated Approval (Subpart H) Priority Review Fast Track TABLE 7 NUMBER AND TOTAL APPROVAL TIME (IN MONTHS) OF APPROVED NDAS AND BLAS, BY FISCAL YEAR OF SUBMISSION AND BY REVIEW PROCEDURE Pediatrics U.S. LITIGATION AND CLINICAL TRIALS TABLE 8 INSURANCE COMPANIES OFFERING CLINICAL TRIAL LIABILITY INSURANCE INVESTIGATIONAL REVIEW BOARD (IRB) EUROPEAN REGULATIONS JAPANESE REGULATIONS GLOBAL REGULATORY STANDARDS INTERNATIONAL CONFERENCE OF HARMONIZATION (ICH) International Conference of Harmonization (Continued) CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30

3 MANAGING CLINICAL TRIALS CONTRACT RESEARCH ORGANIZATIONS (CROS) CLINICAL TRIAL RESEARCH THERAPEUTIC AREAS FIGURE 4 PHRMA MEMBER R&D FUNDING BY THERAPEUTIC CATEGORY, 2010 (% SHARE) TABLE 9 BEST-SELLING PHARMACEUTICAL DRUGS WORLDWIDE, 2009 ($ BILLIONS) TRENDS IN CLINICAL TRIALS ELECTRONIC DATA CAPTURE (EDC) CLINICAL TRIAL COSTS FACTORS INFLUENCING CLINICAL TRIAL COSTS Factors Increasing Clinical Trial Costs Factors Increasing Clinical (Continued) Factors Decreasing Clinical Trial Costs RECENT AND FUTURE TRENDS IN CLINICAL TRIAL PROCESSES RESEARCH AND DEVELOPMENT BUDGETS TABLE 10 INVESTMENT IN R&D AS A PERCENT OF SALES, PHARMACEUTICAL INDUSTRY, THROUGH 2014 (%) TABLE 11 INVESTMENT IN R&D AS A PERCENT OF SALES, PHARMACEUTICAL INDUSTRY, THROUGH 2014, PHRMA MEMBERS, (%) FUNDING CLINICAL TRIALS TABLE 12 TOTAL R&D SPENDING BY SOURCE, THROUGH 2014 ($ BILLIONS) TABLE 13 ESTIMATES OF NIH RESEARCH FUNDING FOR TOP 50 CONDITIONS AND DISEASE CATEGORIES, RESEARCH/DISEASE AREAS, THROUGH 2010 ($ MILLIONS/ROUNDED) BIOTECH/PHARMACEUTICAL COMPANIES TABLE 14 U.S. MARKET FORECAST OF REGISTERED CLINICAL TRIALS SPONSORED BY INDUSTRY BY PHASE, THROUGH 2014 (RECRUITING SUBJECTS) NATIONAL INSTITUTES OF HEALTH AND OTHER FEDERAL AGENCIES OF THE FEDERAL GOVERNMENT TABLE 15 U.S. MARKET FORECAST OF REGISTERED CLINICAL TRIALS SPONSORED BY FEDERAL GOVERNMENT BY PHASE, THROUGH 2014 (RECRUITING SUBJECTS) PRIVATE ORGANIZATIONS, UNIVERSITIES, AND SPECIALTY GROUPS TABLE 16 U.S. MARKET FORECAST OF REGISTERED CLINICAL TRIALS SPONSORED BY UNIVERSITIES OR OTHER ORGANIZATIONS BY PHASE, THROUGH 2014 (RECRUITING SUBJECTS)... 44

4 TABLE 17 TOP 25 FOUNDATIONS AWARDING U.S.-FOCUSED GRANTS FOR GLOBAL HEALTH, RANKED BY NUMBER OF GRANTS AND DOLLAR AMOUNT, Private Organizations, Universities (Continued) CHAPTER FIVE: CLINICAL TRIAL PIPELINES AND TECHNOLOGY TRENDS DRUGS BY SYSTEM CARDIOVASCULAR PhRMA Facts PhRMA Facts (Continued) TABLE 18 SELECTED CARDIOVASCULAR THERAPEUTICS IN DEVELOPMENT, CANCER PhRMA Facts PhRMA Facts (Continued) TABLE 19 SELECTED ANTICANCER CRUGS IN DEVELOPMENT, CENTRAL NERVOUS SYSTEM PhRMA Facts TABLE 20 SELECTED CENTRAL NERVOUS SYSTEM THERAPEUTICS IN DEVELOPMENT, INFECTION INFLAMMATION RESPIRATORY TABLE 21 CDER PRIORITY DRUG AND BIOLOGIC APPROVALS: CALENDAR YEAR TABLE 21 (CONTINUED) DEVICES BIOMEMS STENTS IMPLANTS TABLE 22 MEDICAL DEVICES CLEARED OR APPROVED BY FDA IN TABLE 22 (CONTINUED) TABLE 23 TOP MEDICAL DEVICE COMPANIES, IN TERMS OF 2009 REVENUES ($ MILLIONS) BIOTECHNOLOGY VERSUS PHARMACEUTICAL BIOLOGICS TABLE 24 SELECTED BIOLOGICS IN DEVELOPMENT, TABLE 25 BIOTECHNOLOGY CANDIDATES IN DEVELOPMENT BY MODALITY, TABLE 26 BIOTECHNOLOGY CANDIDATES IN DEVELOPMENT BY INDICATION, TECHNOLOGIES... 62

5 TABLE 27 NUMBER OF CLINICAL TRIALS USING NEW TECHNOLOGIES, THROUGH TABLE 28 NEW TECHNOLOGIES AND PROJECTED EFFECT ON CLINICAL TRIALS ANTISENSE APOPTOSIS BIOCHIPS/MICROARRAYS BIOINFORMATICS BIOPROCESSORS CELLS AND CELL SIGNALING CELL THERAPY (I.E., STEM CELLS, TISSUE REPAIR) CHEMICAL GENOMICS CYTOMICS ELECTRONIC DATA CAPTURE AND E-SUBMISSION GENE THERAPY GENOMICS NOVEL DRUG DELIVERY SYSTEMS PROTEOMICS Four-part Definition of Proteomics THERANOSTICS TRANSGENICS NANOTECHNOLOGY NATURAL SOURCES BIOMARKERS CONSORTIUM NIH Public-Private Partnerships Policy Statement FACTORS INFLUENCING DRUG DEVELOPMENT FIGURE 5 FACTORS INFLUENCING DRUG DEVELOPMENT EPIDEMIOLOGICAL TRENDS LEGISLATION NEW TECHNOLOGIES BIOTERRORISM CHAPTER SIX: CONTRACT RESEARCH ORGANIZATIONS AND GLOBALIZATION CONTRACT RESEARCH ORGANIZATIONS AND GLOBALIZATION CONTRACT RESEARCH ORGANIZATIONS (CONTINUED) ASSOCIATION OF CLINICAL RESEARCH ORGANIZATIONS FACTS ASSOCIATION OF CLINICAL RESEARCH (CONTINUED) TABLE 29 TOP TEN CROS BY REVENUES, GLOBALIZATION TABLE 30 CLINICAL TRIALS WITH OPEN ENROLLMENT BY REGION, JULY OUTSOURCING CLINICAL TRIALS TO FOREIGN COUNTRIES... 78

6 TABLE 31 CLINICAL TRIALS RECRUITING SUBJECTS IN TARGETED COUNTRIES, JULY TABLE 31 (CONTINUED) TABLE 32 AVERAGE COST PER PATIENT FOR TRIALS IN THE U.S., CANADA, AND WESTERN EUROPE FOR ALL THERAPEUTIC AREAS, THROUGH 2014 ($) Advantages Costs TABLE 33 AVERAGE COST PER PATIENT FOR TRIALS IN REDUCED COST COUNTRIES, THROUGH 2014 ($) Efficiency Disadvantages Sociopolitical Issues BRAZIL Patent Protection Pharmaceutical and Clinical Trial Registration Clinical Trials TABLE 34 BRAZILIAN DOMESTIC PHARMACEUTICAL COMPANIES CHINA Patent Protection Pharmaceutical and Clinical Trial Registration Clinical Trials Leading Chinese Pharmaceutical Companies Beijing Double-Crane Pharmaceutical (DCPC) Northeast General Pharmaceutical Sanjiu Medical and Pharmaceutical Co., Ltd C & O Pharmaceutical Technology Holdings Ltd Shijiazhuang Pharma Group Wuxi Pharmatech Harbin Pharmaceutical Group Co INDIA Advantages Disadvantages Key Points for Doing Clinical Studies in India TABLE 35 INDIAN DOMESTIC PHARMACEUTICAL PRODUCERS TABLE 36 INDIA S DOMESTIC PHARMACEUTICAL MARKET (12 MONTHS ENDED JANUARY 2009) TABLE 37 TOP FIVE BIOTECHNOLOGY COMPANIES IN INDIA ROMANIA Patent Protection RUSSIA Patent Protection TABLE 38 LEADING RUSSIAN PHARMACEUTICAL COMPANIES CHAPTER SEVEN: BIOTECHNOLOGY COMPANIES... 89

7 ACTELION PHARMACEUTICALS, LTD TABLE 39 CLINICAL PIPELINE AS OF 12/31/ ALEXION PHARMACEUTICALS, INC TABLE 40 CLINICAL PIPELINE AS OF 12/31/ ALLERGAN, INC TABLE 41 CLINICAL PIPELINE AS OF 12/31/ TABLE 41 (CONTINUED) ALSERES PHARMACEUTICALS, INC TABLE 42 CLINICAL PIPELINE AS OF 12/31/ AMGEN TABLE 43 CLINICAL PIPELINE AS OF 12/31/ TABLE 43 (CONTINUED) ARQULE TABLE 44 CLINICAL PIPELINE AS OF 12/31/ ARRAY BIOPHARMA TABLE 45 CLINICAL PIPELINE AS OF 12/31/ AVANIR PHARMACEUTICALS TABLE 46 CLINICAL PIPELINE AS OF 12/31/ BAXTER BIOSCIENCE TABLE 47 SAMPLE OF BAXTER S CLINICAL TRIALS IN PROGRESS, AUGUST TABLE 47 (CONTINUED) TABLE 47 (CONTINUED) BIOCON TABLE 48 CLINICAL PIPELINE AS OF 12/31/ BIOGEN IDEC TABLE 49 CLINICAL PIPELINE AS OF 12/31/ TABLE 49 (CONTINUED) CELGENE CORP TABLE 50 CLINICAL PIPELINE AS OF 12/31/ CELL THRAPEUTICS TABLE 51 CLINICAL PIPELINE AS OF 12/31/ CELLDEX THERAPEUTICS TABLE 52 CLINICAL PIPELINE AS OF 12/31/ CEPHALON, INC TABLE 53 CLINICAL PIPELINE AS OF 12/31/ CSL BEHRING (CSL, LTD) TABLE 54 CLINICAL PIPELINE AS OF 12/31/ CYTOKINETICS TABLE 55 CLINICAL PIPELINE AS OF 12/31/ DENDREON TABLE 56 CLINICAL PIPELINE AS OF 12/31/ DYNAVAX TECHNOLOGIES TABLE 57 CLINICAL PIPELINE AS OF 12/31/

8 ELAN TABLE 58 CLINICAL PIPELINE AS OF 12/31/ ENZON PHARMACEUTICALS TABLE 59 CLINICAL PIPELINE AS OF 12/31/ EPICEPT CORPORATION TABLE 60 CLINICAL PIPELINE AS OF 12/31/ GENENTECH TABLE 61 CLINICAL PIPELINE AS OF 12/31/ TABLE 61 (CONTINUED) GENZYME TABLE 62 CLINICAL PIPELINE AS OF 12/31/ GILEAD TABLE 63 CLINICAL PIPELINE AS OF 12/31/ GTC BIOTHERAPEUTICS, INC TABLE 64 CLINICAL PIPELINE AS OF 12/31/ GTX TABLE 65 CLINICAL PIPELINE AS OF 12/31/ HUMAN GENOME SCIENCES TABLE 66 CLINICAL PIPELINE AS OF 12/31/ IDERA PHARMACEUTICALS, INC TABLE 67 CLINICAL PIPELINE AS OF 12/31/ IMMUNOGEN, INC TABLE 68 CLINICAL PIPELINE AS OF 12/31/ IMMUNOMEDICS, INC TABLE 69 CLINICAL PIPELINE AS OF 12/31/ LORUS THERAPEUTICS INC TABLE 70 CLINICAL PIPELINE AS OF 12/31/ MAXYGEN TABLE 71 CLINICAL PIPELINE AS OF 12/31/ MYRIAD PHARMACEUTICALS, INC TABLE 72 CLINICAL PIPELINE AS OF 12/31/ NOVO NORDISK A/S TABLE 73 CLINICAL PIPELINE AS OF 12/31/ NPS PHARMACEUTICALS, INC TABLE 74 CLINICAL PIPELINE AS OF 12/31/ REPLIGEN CORPORATION TABLE 75 CLINICAL PIPELINE AS OF 12/31/ SANGAMO BIOSCIENCES, INC TABLE 76 CLINICAL PIPELINE AS OF 12/31/ SEATTLE GENETICS, INC TABLE 77 CLINICAL PIPELINE AS OF 12/31/ TALECRIS BIOTHERAPEUTICS, INC TABLE 78 CLINICAL PIPELINE AS OF 12/31/ UCB SA

9 TABLE 79 CLINICAL PIPELINE AS OF 12/31/ URIGEN PHARMACEUTICALS, INC TABLE 80 CLINICAL PIPELINE AS OF 12/31/ VERTEX PHARMACEUTICALS INCORPORATED TABLE 81 CLINICAL PIPELINE AS OF 12/31/ VICAL, INCORPORATED TABLE 82 CLINICAL PIPELINE AS OF 12/31/ XOMA, LTD TABLE 83 CLINICAL PIPELINE AS OF 12/31/ CHAPTER EIGHT: PHARMACEUTICAL COMPANIES ABBOTT LABORATORIES TABLE 84 CLINICAL PIPELINE HIGHLIGHTS AS OF 8/ ASTRAZENECA PLC TABLE 85 CLINICAL PIPELINE AS OF 12/31/ TABLE 85 (CONTINUED) TABLE 85 (CONTINUED) TABLE 85 (CONTINUED) BAYER SCHERING PHARMA AG TABLE 86 PHASE II/III CLINICAL PIPELINE AS OF 12/31/ TABLE 86 (CONTINUED) BOEHRINGER INGELHEIM GMBH TABLE 87 CLINICAL PIPELINE AS OF 12/31/ BRISTOL-MYERS SQUIBB COMPANY TABLE 88 CLINICAL PIPELINE, SELECTED PHASE I/II CANDIDATES AS OF 12/31/ TABLE 88 (CONTINUED) TABLE 89 INVESTIGATIONAL CANDIDATES IN PHASE III CLINICAL TRIALS ELI LILLY AND COMPANY TABLE 90 CLINICAL PIPELINE HIGHLIGHTS AS OF 8/ GLAXOSMITHKLINE PLC TABLE 91 CLINICAL PIPELINE AS OF 12/31/ TABLE 91 (CONTINUED) TABLE 91 (CONTINUED) TABLE 91 (CONTINUED) TABLE 91 (CONTINUED) JOHNSON & JOHNSON TABLE 92 SELECTED PHASE III CLINICAL PIPELINE AS OF 12/31/ MERCK & CO., INC TABLE 93 CLINICAL PIPELINE AS OF 12/31/ TABLE 93 (CONTINUED) MERCK SERONO TABLE 94 CLINICAL PIPELINE AS OF 12/31/

10 NOVARTIS AG TABLE 95 CLINICAL PIPELINE AS OF 12/31/ TABLE 95 (CONTINUED) TABLE 95 (CONTINUED) TABLE 95 (CONTINUED) TABLE 95 (CONTINUED) PFIZER, INC TABLE 96 CLINICAL PIPELINE AS OF 12/31/ TABLE 96 (CONTINUED) TABLE 96 (CONTINUED) TABLE 96 (CONTINUED) ROCHE TABLE 97 CLINICAL PIPELINE AS OF 12/31/ TABLE 97 (CONTINUED) TABLE 97 (CONTINUED) SANOFI-AVENTIS TABLE 98 CLINICAL PIPELINE AS OF 12/31/ TABLE 98 (CONTINUED) TAKEDA PHARMACEUTICAL COMPANY LIMITED TABLE 99 CLINICAL PIPELINE AS OF 12/31/ TABLE 99 (CONTINUED) TABLE 99 (CONTINUED) TABLE 99 (CONTINUED) CHAPTER NINE: MEDICAL EQUIPMENT AND DEVICES TABLE 100 MEDICAL EQUIPMENT AND DEVICE COMPANIES IN THE U.S. WITH ANNUAL REVENUES EXCEEDING $1 BILLION TABLE 100 (CONTINUED) TABLE 100 (CONTINUED) TABLE 100 (CONTINUED) CHAPTER TEN: CLINICAL RESEARCH ORGANIZATIONS TOP 10 CROS TABLE 101 TOP 10 CROS BY REVENUE (ACCOUNTED FOR MORE THAN 50% OF TOTAL INDUSTRY REVENUE IN 2008/2009) SECONDARY CROS (ALPHABETICAL ORDER) TABLE 102 SECONDARY CROS (ALPHABETICAL ORDER) TABLE 102 (CONTINUED) NICHE CRO SPECIALIZED BY REGION OR THERAPEUTIC FOCUS (ALPHABETICAL ORDER) TABLE 103 NICHE CRO SPECIALIZED BY REGION OR THERAPEUTIC FOCUS (ALPHABETICAL ORDER) TABLE 103 (CONTINUED) TABLE 103 (CONTINUED) TABLE 103 (CONTINUED)

11 TABLE 103 (CONTINUED) TABLE 103 (CONTINUED)

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

ehealthinsight Series: Online Patient Recruitment Strategies

ehealthinsight Series: Online Patient Recruitment Strategies A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient

More information

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:

More information

The Hong Kong Association of The Pharmaceutical Industry

The Hong Kong Association of The Pharmaceutical Industry The Hong Kong Association of The Pharmaceutical Industry UNIT A, 20/F., TIMES MEDIA CENTRE, FAX: (852) 2865 6283 WEBSITE: www. hkapi.hk Position Paper on the Pharmacy and Poisons (Amendment) Bill 2014

More information

DRUGS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS: GLOBAL MARKETS

DRUGS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS: GLOBAL MARKETS DRUGS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS: GLOBAL MARKETS PHM159A March 2014 Sanjukta Bhattacharyya Project Analyst ISBN: 1-56965-754-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report /wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天

More information

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for

More information

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics

More information

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials

More information

Pharma working capital performance highly variable

Pharma working capital performance highly variable April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the

More information

KEEPING CLINICAL TRIALS IN AUSTRALIA

KEEPING CLINICAL TRIALS IN AUSTRALIA OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought

More information

Industry Insight - Indian Biopharma

Industry Insight - Indian Biopharma Brochure More information from http://www.researchandmarkets.com/reports/2043221/ Industry Insight - Indian Biopharma Description: Biopharmaceuticals are complex macromolecules (Large molecules) created

More information

In the largest and perhaps the most ambitious collaborative

In the largest and perhaps the most ambitious collaborative FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

More information

The Future of R&D Outsourcing

The Future of R&D Outsourcing OUTSOURCING The Future of R&D Outsourcing Investigating development hurdles, key challenges & strategies to optimize CRO relationships By Alison Sahoo Alison Sahoo Alison Sahoo is a pharmaceutical industry

More information

Rx-360 An International Pharmaceutical Supply Chain Consortium

Rx-360 An International Pharmaceutical Supply Chain Consortium Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)

More information

PEDIATRIC MEDICINES: GLOBAL MARKETS

PEDIATRIC MEDICINES: GLOBAL MARKETS PEDIATRIC MEDICINES: GLOBAL MARKETS PHM170A October 2014 Dr. Cheryl Lee Barton Project Analyst ISBN: 1-56965-971-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global Content Management in the Pharmaceutical Industry An Overview Blockbuster!!! Avatar USD 2 Billion revenues Lipitor USD 12.5 Billion in 2008 Dr Arun Gangatkar http://in.linkedin.com/in/drarungangatkar drarunj@gmail.com

More information

Pharma working capital leaves room for improvement

Pharma working capital leaves room for improvement October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.

More information

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be

More information

Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report

Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1382330/ Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report Description: This report analyzes the Global market

More information

Excellence in Oncology Clinical Trials

Excellence in Oncology Clinical Trials Oncology Clinical Trials We work to find a better way. We work to raise standards and deliver more. We break new ground to make progress possible. Oncology Research ICON is a global provider of outsourced

More information

Global Monoclonal Antibodies Pipeline Insight 2015

Global Monoclonal Antibodies Pipeline Insight 2015 Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who

More information

Medical Writing Takes Off in India

Medical Writing Takes Off in India Visit http://store.centerwatch.com to learn more about State of the Clinical Trials Industry 2008 Special Article Reprint For the latest news and views on the clinical trials industry visit ClinicalTrialsToday.com

More information

RNCOS Online Business Research

RNCOS Online Business Research RNCOS Page 1 of 18 About Us RNCOS, formed in the year 2002, aims to outsource all your business needs and serve your customers in their quest for the information. RNCOS is transforming the concept of Outsourcing

More information

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?

More information

Emerging Clinical Sites: India and China. Patrycja Doba, Clinical Research Coordinator

Emerging Clinical Sites: India and China. Patrycja Doba, Clinical Research Coordinator Emerging Clinical Sites: India and China Patrycja Doba, Clinical Research Coordinator Overview 1. Outsourcing trends in Pharmaceutical Industry 2. Reasons for outsourcing 3. The most outsourced activity

More information

Key Findings. Use this report to... The Top 10 Contract Research Organizations

Key Findings. Use this report to... The Top 10 Contract Research Organizations Key Findings The global CRO industry valued $18bn in 2008, an increase of 14% over 2007. The CRO market will grow at an annual rate of 14% over the 2009 13 period. Quintiles leads the global CRO market

More information

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality 6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors

More information

Multiple Sclerosis Treatments: World Market Outlook to 2011

Multiple Sclerosis Treatments: World Market Outlook to 2011 Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating

More information

Pharmaceutical Marketing Disclosures

Pharmaceutical Marketing Disclosures Pharmaceutical Marketing Disclosures July 1, 2007 June 30, 2008 Report of Vermont Attorney General William H. Sorrell April 2009 Prepared by staff of the Vermont Attorney General s Office: Wendy Morgan,

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW

CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW April 2014 Investment banking services are provided by Harris Williams LLC, a registered broker-dealer and member of FINRA and SIPC, and Harris Williams

More information

ORPHAN DRUG. ORPHAN DRUG & RARE DISEASE DEVELOPMENT: Understanding the U.S. and European Regulatory Landscape & RARE DISEASE DEVELOPMENT

ORPHAN DRUG. ORPHAN DRUG & RARE DISEASE DEVELOPMENT: Understanding the U.S. and European Regulatory Landscape & RARE DISEASE DEVELOPMENT : Abstract Today, more than ever, researchers are focused on providing care for the approximately 7,000 rare diseases that may have been overlooked in the past due to the challenges of conducting clinical

More information

Global Peptide Therapeutics Market 2014-2018

Global Peptide Therapeutics Market 2014-2018 Brochure More information from http://www.researchandmarkets.com/reports/3022209/ Global Peptide Therapeutics Market 2014-2018 Description: About Peptide Therapeutics Peptides are amino acids sequences

More information

Target Product Profile (TPP) Process. Dr. Michele Sharp, PharmD, Sr. Director, Regulatory Affairs, Eli Lilly and Company

Target Product Profile (TPP) Process. Dr. Michele Sharp, PharmD, Sr. Director, Regulatory Affairs, Eli Lilly and Company Target Product Profile (TPP) Process Dr. Michele Sharp, PharmD, Sr. Director, Regulatory Affairs, Eli Lilly and Company 1 Disclaimer The views and opinions expressed in the following PowerPoint slides

More information

La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente?

La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente? La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente? 57 Congresso Nazionale SIGG Società Italiana di Gerontologia e Geriatria Dr. Marco Scatigna Direttore Medico e

More information

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Commercial Insight Osteoarthritis and Rheumatoid Arthritis A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and

More information

Brochure More information from http://www.researchandmarkets.com/reports/3292678/

Brochure More information from http://www.researchandmarkets.com/reports/3292678/ Brochure More information from http://www.researchandmarkets.com/reports/3292678/ Asia Pacific (India, China, Australia, South Korea & Others) Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long

More information

The United States False Claims Act Qui Tam Whistleblower Law

The United States False Claims Act Qui Tam Whistleblower Law The United States False Claims Act Qui Tam Whistleblower Law Getnick & Getnick LLP Counsellors At Law Rockefeller Center, 620 Fifth Avenue New York, NY 10020 Phone: (212) 376-5666 Fax: (212) 292 3942 www.getnicklaw.com

More information

BIOMARKERS & MOLECULAR TUMOUR CLASSIFICATION FOR NON-GENOTOXIC CARCINOGENESIS

BIOMARKERS & MOLECULAR TUMOUR CLASSIFICATION FOR NON-GENOTOXIC CARCINOGENESIS MARCAR BIOMARKERS & MOLECULAR TUMOUR CLASSIFICATION FOR NON-GENOTOXIC CARCINOGENESIS What patients need What Europe needs Improved drug safety Increased efficiency of drug development Earlier detection

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

EU Clinical Trials Register

EU Clinical Trials Register EU Clinical Trials Register Sponsor Contact Information Abbott Laboratories Ltd Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4XE UK Telephone number +44 1628 644475 euclinicaltrials@abbott.com

More information

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Metastatic Breast Cancer - Pipeline Review, Q1 2011 Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary

More information

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013 Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory

More information

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

PHARMACEUTICAL INDUSTRY PROFILE

PHARMACEUTICAL INDUSTRY PROFILE PHARMACEUTICAL INDUSTRY PROFILE I. INDUSTRY BACKGROUND A. Industry Definition The U.S. pharmaceutical industry is defined by the Census Bureau as companies engaged in researching, developing, manufacturing,

More information

IMMUNOCHEMICALS - A Global Strategic Business Report

IMMUNOCHEMICALS - A Global Strategic Business Report /wepdwukltuyot IMMUNOCHEMICALS - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天 地 大 厦 A2 座 1008-1 室 (100080) 出 版 日 期 :April 2011

More information

Biopharmaceutical Raw Materials throughout the Product Lifecycle

Biopharmaceutical Raw Materials throughout the Product Lifecycle February 27 March 2, 2012 Hilton San Diego Bayfront San Diego, CA Monday Tuesday Programming: IBC s 17th International Process & Analytical Assay Validation IBC s 8th International Outsourcing Manufacturing

More information

The World's Top 100 Pharmaceutical Companies

The World's Top 100 Pharmaceutical Companies Brochure More information from http://www.researchandmarkets.com/reports/1878687/ The World's Top 100 Pharmaceutical Companies Description: Did you know? - Dr. Jeremy Levin is Senior Vice President, Strategy,

More information

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Brochure More information from http://www.researchandmarkets.com/reports/2904677/ Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Pleural Mesothelioma - Pipeline Review,

More information

An integrated global healthcare company

An integrated global healthcare company An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment

More information

Trade Sales of Biotechnology and Specialty Pharma Companies 2005-2008

Trade Sales of Biotechnology and Specialty Pharma Companies 2005-2008 HBM / M&A Survey Trade Sales of nology and Specialty Companies -8 Further information about the survey including a list of transactions can be found under www.hbmpartners.com/survey. The use of data and

More information

Exhibitors. Key Speakers:

Exhibitors. Key Speakers: Key Speakers: Paul Dolin, Head of Pharmacoepidemiology, Takeda Pharmaceuticals Sandip Chaudhari, Senior Director and Clinical Safety and Risk Management, Pfizer Dr. Katrin Freund, Project Excellence Manager

More information

Multiple Sclerosis Drug Discoveries - What the Future Holds

Multiple Sclerosis Drug Discoveries - What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally

More information

Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies

Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial

More information

Ross Career Services. Health Care. Introduction. Health Care Overview

Ross Career Services. Health Care. Introduction. Health Care Overview Ross Career Services Career Path: Health Care Introduction Ross Career Services (RCS) created the Career Path series to assist students with the career search process. Each Career Path (online) handout

More information

Pharmaceutical industry

Pharmaceutical industry 8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and

More information

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many

More information

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical

More information

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life

More information

9. WestLB Deutschland Conference. Frankfurt November 16, 2011

9. WestLB Deutschland Conference. Frankfurt November 16, 2011 9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Annual Press Conference 2012. Business Year 2011

Annual Press Conference 2012. Business Year 2011 Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation

More information

Pharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch

Pharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch Pharmaceutical Products Liability Michael C. Dubin Stephen Knobloch Objectives Objective 1 Get Actuaries Thinking About Adding Value to New Areas Objective 2 Provide example using pharmaceutical industry

More information

MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME

MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME FOR IMMEDIATE RELEASE MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME - $185 Million Collaboration to Determine All Human Protein Interactions And Decipher Biochemical Pathways

More information

In-depth analysis of the report is based on propriety databases, primary and secondary research and inhouse analysis by a team of experts.

In-depth analysis of the report is based on propriety databases, primary and secondary research and inhouse analysis by a team of experts. Brochure More information from http://www.researchandmarkets.com/reports/1882193/ Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising

More information

Roots Analysis Pvt. Ltd.

Roots Analysis Pvt. Ltd. Roots Analysis Pvt. Ltd. http://www.marketresearch.com/rootsanalysispvt.ltd. -v3981/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am

More information

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 PHARMAPACK 2015 1 Mobile health x2 30 months 100 000 mapps Source: research2guidance, mhealth App Market Report 2013-2017

More information

Biometrics: Clinical Trials and Beyond

Biometrics: Clinical Trials and Beyond Biometrics: Clinical Trials and Beyond Statistics, Programming, and Data Management in Research, Development, and Regulatory Submissions. For all, Not Just Statisticians! Keynote Presentations Sue-Jane

More information

TABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.

TABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1. 1 Disclaimer The research reports provided by AM Mindpower Solutions are for the personal information of the authorised recipient and is not for public distribution and should not be reproduced or redistributed

More information

Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure

Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National

More information

GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES - FOCUS ON INSULIN PENS. HLC157A August 2013. Shalini Shahani Dewan Project Analyst

GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES - FOCUS ON INSULIN PENS. HLC157A August 2013. Shalini Shahani Dewan Project Analyst GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES - FOCUS ON INSULIN PENS HLC157A August 2013 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-531-6 BCC Research 49 Walnut Park, Building

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

OPPORTUNITY AFRICAN MARKET FOR INDIAN COMPANIES

OPPORTUNITY AFRICAN MARKET FOR INDIAN COMPANIES OPPORTUNITY AFRICAN MARKET FOR INDIAN COMPANIES G.K. Raman Regional Director PHARMEXCIL INDIAN PHARMACEUTICAL INDSTRY Manufacturers over 400 APIs (BULK DRUGS) Manufacturers over 10,000 medicaments (Formulations)

More information

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends Symposium Life Science am Kapitalmarkt Frankfurt, 3. Juni 28 Global biotech industry Strong growth in most areas but Visible product

More information

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Brochure More information from http://www.researchandmarkets.com/reports/1383065/ Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Description: Introduction Disease-modifying

More information

Life Sciences Outlook. New Jersey 2015

Life Sciences Outlook. New Jersey 2015 Life Sciences Outlook New Jersey 2015 New Jersey M&A activity in New Jersey has led to the consolidation of surplus real estate holdings and diminished head counts. However, midsized companies are helping

More information

4 th Annual Clinical Development and Trials Asia Congress. 5 th Annual Pharma R&D World Asia Congress

4 th Annual Clinical Development and Trials Asia Congress. 5 th Annual Pharma R&D World Asia Congress Oxford Global Medical Conferences Imaging technologies are proud to present the 4 th Annual Clinical Development and Trials Asia Congress and Implementing biomarkers in co-located early phase Pharma clinical

More information

Global Pharmaceuticals Marketing Channel Reference EDITION

Global Pharmaceuticals Marketing Channel Reference EDITION Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry

More information

Breakthrough Therapy Program U.S. Food and Drug Administration (FDA)

Breakthrough Therapy Program U.S. Food and Drug Administration (FDA) Breakthrough Therapy Program U.S. Food and Drug Administration (FDA) Presentation before the European Commission Expert Group on Safe and Timely Access to Medicines for Patients (STAMP) Jarilyn Dupont,

More information

The 2015 Avoca Report. Clinical Development Innovation. Sponsor and Provider Views on Innovation in Outsourced Clinical Development

The 2015 Avoca Report. Clinical Development Innovation. Sponsor and Provider Views on Innovation in Outsourced Clinical Development The 2015 Avoca Report Clinical Development Innovation Sponsor and Provider Views on Innovation in Outsourced Clinical Development Contents Section Slides Research Overview 3-5 Respondent Demographics 6-9

More information

Global and China Stem Cell Industry Report, 2014-2017. Sep. 2014

Global and China Stem Cell Industry Report, 2014-2017. Sep. 2014 Global and China Stem Cell Industry Report, 2014-2017 Sep. 2014 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight

More information

Emerging Business Models in the Pharmaceutical Industries. Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players

Emerging Business Models in the Pharmaceutical Industries. Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players Emerging Business Models in the Pharmaceutical Industries Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players JSB Intelligence Kildare House, 102-104 Sheen Road Richmond, TW9

More information

Directory of Clinical Research Companies In India

Directory of Clinical Research Companies In India Directory of Clinical Research Companies In India December 2005 4 th & 5 th Floors, Astral Heights, Road No. 1, Banjara Hills, Hyderabad-500034, India Tel: +91-40-23430203-07, Fax: +91-40-23430208, E-mail:

More information

Adjudication in Oncology Trials: A Concept Whose Time Has Come

Adjudication in Oncology Trials: A Concept Whose Time Has Come Adjudication in Oncology Trials: A Concept Whose Time Has Come By WorldCare Clinical: Richard Walovitch, PhD, Chief Medical Officer, Asli Memisoglu, ScD, Director of Biostatistics and Data Management,

More information

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm A Datamonitor report Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm Published: Sep-06 Product Code: Providing you with: Disease overview including epidemiology, physician

More information

Carol Lefebvre Senior Information Specialist UK Cochrane Centre National Institute for Health Research Oxford, UK

Carol Lefebvre Senior Information Specialist UK Cochrane Centre National Institute for Health Research Oxford, UK Clinical trials registers and clinical trials results registers: their contribution as health information sources to evidence-based healthcare decision-making Carol Lefebvre Senior Information Specialist

More information

An Introduction to Genomics and SAS Scientific Discovery Solutions

An Introduction to Genomics and SAS Scientific Discovery Solutions An Introduction to Genomics and SAS Scientific Discovery Solutions Dr Karen M Miller Product Manager Bioinformatics SAS EMEA 16.06.03 Copyright 2003, SAS Institute Inc. All rights reserved. 1 Overview!

More information

Indian Vaccines Report

Indian Vaccines Report Brochure More information from http://www.researchandmarkets.com/reports/595558/ Indian Vaccines Report Description: "Vaccine manufacturers from all over the world have been involved in a stalemate with

More information

Sage ERP I White Paper

Sage ERP I White Paper The Premier Provider of Effective Business Software Solutions National Presence, Local Touch 1.800.4.BLYTHE www.blytheco.com I White Paper Proactive Regulatory Compliance for Biopharmaceutical Global Competitiveness

More information

Christopher Kratochvil, MD, Assistant Vice Chancellor for Clinical Research Deborah Vetter, MS, Director, Sponsored Programs Administration

Christopher Kratochvil, MD, Assistant Vice Chancellor for Clinical Research Deborah Vetter, MS, Director, Sponsored Programs Administration Christopher Kratochvil, MD, Assistant Vice Chancellor for Clinical Research Deborah Vetter, MS, Director, Sponsored Programs Administration Clinical Research Center Learn-At-Lunch Series October 13, 2011

More information

Clinical Supply Chain Management. Technologies such as IVRS, CTMS, EDC and RFID Enhance Drug Supply Management

Clinical Supply Chain Management. Technologies such as IVRS, CTMS, EDC and RFID Enhance Drug Supply Management Clinical Supply Chain Management Technologies such as IVRS, CTMS, EDC and RFID Enhance Drug Supply Management GBI Research Report Guidance GBI Research Report Guidance The report focuses on the current

More information

Stakeholder Insight: Insulin Use in Type 2 Diabetes

Stakeholder Insight: Insulin Use in Type 2 Diabetes A Datamonitor Report Stakeholder Insight: Insulin Use in Type 2 Diabetes From Last Resort to Early Intervention Published: May-04 Product Code: DMHC1989 Providing you with: Analysis of Datamonitor s Diabetes

More information

Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada

Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D Globalization of Clinical Research: Trends & Implications for Success Rates by Phase and Therapeutic Area Source: Nature Reviews Drug

More information

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute

More information